Led · Equity · Feb 2026

Founded in 2021, Honest Health partners with hospitals and provider groups to navigate value-based, risk-bearing reimbursement models. Its platform supplies clinicians with actionable analytics, operational support, and shared-accountability structures that prioritize quality and cost containment over volume. Led by CEO Rob Bessler, M.D., and backed by founders from Rubicon Founders, the company combines deep clinical expertise with scalable technology infrastructure. Honest Health’s services include care coordination tools and performance dashboards designed to improve patient outcomes and financial performance for health systems. The company has rapidly gained traction, prompting sizable investor interest. Proceeds from its latest funding will be used to expand into additional U.S. markets, form new partnerships with payers and providers, and further develop its technology and service offerings. No revenue or user metrics were disclosed in the article, but management cites “measurable improvements” in outcomes and cost savings as evidence of early success.

Led · Series B · Nov 2025

Founded in 2018, Washington-DC–based Sorcero offers an Agentic AI platform—comprising Sorcero Medical, SciComms, Safety and Medtech—that is specifically trained on life-science data and built to meet stringent regulatory and privacy requirements. The system unifies hundreds of global data sources to create a 360° view of more than 40 million healthcare professionals and 100 million scientists, enabling customers to analyze 263 million publications and 1.3 billion citations for real-time insights. One-third of the top 30 global pharmaceutical firms use Sorcero, achieving up to 92 % productivity gains in evidence generation, 72 % faster insight discovery, and publication timelines shortened by two to five months. The platform delivers 96.1 % clinical inclusion accuracy—exceeding FDA regulatory thresholds and PhD-level human performance. Sorcero’s offerings support medical affairs, safety, scientific communications, and medical devices, and are available directly and through channels such as the Google Cloud Marketplace and NIH STRIDES. Recent strategic moves include the acquisition of Axiom Health to bolster its med-device capabilities and partnerships with Google Cloud, Springer Nature, ServiceNow, USDM Life Sciences, and Snowflake. With a cumulative $59 million raised, the company plans to scale globally and further develop its insight-driven engagement model for precision medicine.

Led · Equity · Sep 2025

Bite Stream is the flagship software platform of Bite Investments and serves as an all-in-one cloud hub for onboarding, communication, reporting, and data management in the private-markets ecosystem. The solution provides a single portal through which limited partners and retail investors can view all of their alternative investments, helping managers raise capital and manage investor relations more efficiently. By replacing fragmented legacy systems, Bite Stream seeks to democratize access to alternative assets and usher in greater transparency and automation across the industry. Fueled by rapid global growth in private-market AUM, the company plans to expand its technology stack, grow its team, and deepen its reach with asset managers worldwide. The newly announced funding reinforces management’s intent to close technology gaps in private markets and deliver a unified investor and manager experience. Although the company has not disclosed revenue or user figures, management emphasizes a long-term vision of combining proven investment expertise with modern software to redefine how alternative-asset stakeholders interact.

Led · Equity · May 2025

Kincell Bio is a scientifically focused CDMO engineering cells into therapies and supporting immune cell programs including autologous and allogeneic CAR‑T, CAR‑NK and CAR‑M, as well as stem cell and iPSC products. Its platform offers personalized, responsive process development and manufacturing from early clinical through pivotal studies and product launch, with services in analytical and process development, GMP manufacturing, testing and release. The company operates manufacturing facilities in Research Triangle Park, NC and Gainesville, FL. Kincell plans to expand its cGMP capabilities and enhance process development services to support emerging cell therapy companies. The recent $22 million investment will accelerate those expansions and support development of innovative solutions tailored to the cell therapy market. Leadership additions, including the appointment of industry veteran Pete Buzy to the board, are positioned to bolster operational expertise as the company scales. Kincell Bio is a CDMO spun out of Inceptor Bio’s CMC, offering analytical development, process development, CMC consulting and early-stage GMP manufacturing for immune cell therapies. The company focuses on autologous and allogeneic CAR-T, CAR-NK and CAR-M programs. Kincell acquired a facility and a fully staffed team at its Gainesville site and plans to grow in Gainesville as well as Research Triangle Park, Boston and other customer locations. The company plans to establish in-house mRNA development and add GMP manufacturing capacity while forging partnerships for viral vector and plasmid DNA supply. Leadership includes CEO Bruce Thompson, Ph.D., who brings over 20 years of CMC strategy and cell therapy manufacturing experience, and board chair Shailesh Maingi of Kineticos Ventures. Kincell emerged from stealth with new funding to support its manufacturing and development expansion.

Led · Series B · Jan 2025

Jones provides AI-driven software to accelerate collection and verification of insurance certificates, endorsements, and policies, integrating bi-directionally with ERP systems. The company combines machine learning with human compliance experts to scale traditionally manual, error-prone processes. Jones has scaled to 25,039 real estate properties and construction projects covering over 2.5 billion square feet in the United States. Its product suite focuses on insurance verification, collection, integration, and decisioning across commercial and residential asset classes. Jones plans to release a suite of GenAI Agents fine-tuned on proprietary insurance data and millions of verified insurance documents to automate routine tasks and enable autonomous decision-making. The company also intends to continue expanding software workflows and deepening ERP integrations to reduce manual workloads and mitigate insurance claims.